Detects TGF-beta 3 from multiple species in direct ELISAs and Western blots. In Western blots, less than 25% cross-reactivity with recombinant human (rh) TGF‑ beta 1.2 and rhTGF-beta 2 is observed, and less than 2% cross‑reactivity with recombinant amphibian TGF-beta 5 and recombinant human TGF-beta 1 is observed. Neutralizes the biological activity of TGF-beta 3 but not TGF-beta 1, TGF-beta 2, or TGF-beta 5.
Monoclonal Mouse IgG1 Clone # 20724
Protein A or G purified from ascites
Spodoptera frugiperda, Sf 21 (baculovirus) derived recombinant human TGF-beta 3 Ala301-Ser412 (Tyr340Phe) Accession # P10600
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human TGF-beta 3 (Catalog # 243-B3) under non-reducing conditions only
Measured by its ability to neutralize TGF‑ beta 3 inhibition of IL‑4-dependent proliferation in the HT‑2 mouse T cell line. Tsang, M. et al. (1995) Cytokine 7:389. The Neutralization Dose (ND50) is typically 0.1-0.3 µg/mL in the presence of 0.1 ng/mL Recombinant Human TGF‑ beta 3 and 7.5 ng/mL Recombinant Mouse IL‑4.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
TGF‑ beta 3 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization by TGF‑ beta 3 Antibody. Recombinant Human TGF‑ beta 3 (Catalog # 243-B3) inhibits Recombinant Mouse IL‑4 (Catalog # 404-ML) induced proliferation in the HT‑2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse IL‑4 (7.5 ng/mL) activity elicited by Recombinant Human TGF‑ beta 3 (0.1 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-TGF‑ beta 3 Monoclonal Antibody (Catalog # MAB243). The ND50 is typically 0.1-0.3 µg/mL.
TGF‑ beta 3 in Human Breast Cancer Tissue. TGF‑ beta 3 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-TGF‑ beta 3 Monoclonal Antibody (Catalog # MAB243) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in cancer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TGF-beta 3
TGF-beta 3 (transforming growth factor beta 3) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cystine knot structure (1‑7). TGF-beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1‑4). Each TGF‑ beta isoform has some non-redundant functions; for TGF-beta 3, mice with targeted deletion show defects palatogenesis and pulmonary development (2). Human TGF-beta 3 cDNA encodes a 412 amino acid (aa) precursor that contains a 20 aa signal peptide and a 392 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 220 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF‑ beta 3 (8, 9). Disulfide-linked homodimers of LAP and TGF-beta 3 remain non-covalently associated after secretion, forming the small latent TGF-beta 3 complex (8‑10). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-beta 3 shows 100%, 99% and 98% aa identity with mouse/dog/horse, rat and pig TGF-beta 3, respectively. It demonstrates cross-species activity.(1) TGF-beta 3 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1.This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors betaglycan (also known as TGF-beta RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-beta in different contexts (11).
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.